Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes

Gao, Jie; Zhong, Wei; He, Jian; Li, Huimei; Zhang, He; Zhou, Guichen; Li, Bohua; Lü, Ying; Zou, Hao; Kou, Geng; Zhang, David; Wang, Hao; Guo, Yajun; Zhong, Yanqiang

doi:10.1016/j.ijpharm.2009.03.018

Cited by 66 publications

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, anti-HER2 Fab' was chosen as the tumor targeting ligand of LPIL. Once anti-HER2 Fab' binding occurs, it was rapidly internalized by HER2-mediated endocytosis and thus was suitable in delivering cytotoxic payloads to intracellular targets, which was well demonstrated by our previous studies [16,24,35]. Second, lyophilization could greatly increase the serum stability of LPIL.…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing

Gao

Sun

et al. 2010

Biomaterials

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 66%

“…Gel chromatography was a common method used to separate unconjugated antibody fragments from liposomes [24]. As showed in Supplementary Fig.…”

Section: Determination Of Anti-her2 Fab' On the Surface Of Liposomesmentioning

confidence: 99%

Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing

Gao

Sun

et al. 2010

Biomaterials

Self Cite

View full text Add to dashboard Cite

“…With respect to immunoliposomes, although many preclinical studies can be found in the literature [24,215,275,276] and a few clinical trials are in progress [18,75,[277][278][279] an siRNA that targets PKN3 [18,286], or TKM-PLK1 that includes siRNA against PLK1 for the treatment of neuroendocrine tumors and adrenocortical carcinomas (phase I/II clinical trials) [283,287,288]. The phase I liposomic formulation SGT-53 includes plasmidic DNA that expresses the tumor suppressor gene p53 to treat solid tumors [280,289].…”

Section: Nl Cpt-11mentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,460

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

“…The uptake of recombinant proteoliposomes by mammalian cells induces apoptosis by release of cytochrome c and activation of caspases. Gao et al [35] formulated Pseudomonas exotoxin-based immunotoxins (PE38KDEL) into PEGylated anti-HER2 Fab´-functionalized liposomes, which showed promising results in the treatment of HER2-overexpressing breast cancers in vitro.…”

Section: Liposomesmentioning

confidence: 99%

Engineering the Nanoparticle-Protein Interface for Cancer Therapeutics

Saie

Ray

Rotello

2015

Cancer Treatment and Research

View full text Add to dashboard Cite

Intracellular delivery of functional proteins using nanoparticles can be a game-changing approach for cancer therapy. However, cytosolic release of functional protein is still a major challenge. In addition, formation of protein corona on the surface of the nanoparticles can also alter the behavior of the nanoparticles. Here, we will review recent strategies for protein delivery into the cell. Finally we will discuss the issue of protein corona formation in light of nanoparticle-protein interactions.

show abstract

Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes

Cited by 66 publications

References 21 publications

Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing

Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Engineering the Nanoparticle-Protein Interface for Cancer Therapeutics

Contact Info

Product

Resources

About